Concepedia

Prospective <i>CYP2C19</i> Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention

Sony Tuteja, Henry A. Glick, William Matthai, Irving Nachamkin, Ashwin S. Nathan, Karen Monono, Craig Carcuffe, Karen Maslowski, Gene Chang, Taisei Kobayashi,

Circulation Genomic and Precision Medicine · 2020 · 57 citations · 27 references

DOIFull text

Open access

Abstract

URL: http://www.clinicaltrials.gov. Unique Identifier: NCT02508116.

References

27

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

Lars Wallentin, Richard C. Becker, Andrzej Budaj et al. · New England Journal of Medicine · 2009 · 7K citations · Full text

Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

Stephen D. Wiviott, Eugene Braunwald, Carolyn H. McCabe et al. · New England Journal of Medicine · 2007 · 6.7K citations · Full text

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

Glenn N. Levine, Eric Bates, James C. Blankenship et al. · Journal of the American College of Cardiology · 2011 · 2.2K citations

, , +6

Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy

Alan R. Shuldiner · JAMA · 2009 · 1.5K citations · Full text

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

Stuart A. Scott, Katrin Sangkuhl, Catherine M. Stein et al. · Clinical Pharmacology & Therapeutics · 2013 · 944 citations · Full text